1. Sweden Stocks

  2. •

    Healthcare

  3. •

    Medical - Diagnostics & Research
AroCell AB (publ)

AroCell AB (publ)

AROC.ST
AroCell AB (publ)SE flagStockholm Stock Exchange
0.57
SEK
- -
- -
132.23MMarket Cap
AroCell AB (publ)
AROC.ST
(Stockholm Stock Exchange)

Recent

price

0.57

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
TTM
FRC
0.01
- -
- -
- -
- -
- -
- -
0.02
0.02
0.01
- -
0.13
0.17
0.19
- -
0.26
Revenue per Share
-0.97
-0.43
-0.22
-0.19
-0.26
-0.25
-0.31
-0.58
-0.51
-0.57
-0.31
-0.53
-0.27
-0.26
- -
-0.19
Basic EPS, GAAP
- -
-0.31
- -
- -
- -
-0.44
-0.57
-0.52
-0.4
-0.42
-0.25
-0.3
-0.08
-0.06
- -
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
-1.2
-0.22
-0.12
-0.1
-0.16
-1.01
-1.64
-2.19
-2.05
-2.85
-1.53
-1.73
-1.01
-1.2
- -
-1.44
Book Value per Share
-0.26
0.02
0.21
0.24
0.73
1.72
1.08
0.59
0.73
1.67
0.53
0.24
0.34
0.25
- -
0.23
Tangible Book Value per Share
2
8
15
19
24
30
30
30
41
36
76
94
215
230
- -
230
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
- -
- -
1
1
- -
- -
12
37
43
57
60
Sales/Revenue/Turnover
-7,786.78
- -
- -
- -
- -
- -
-16,900.68
-3,439.34
-2,654.82
-4,680.59
-28,564.29
-423.61
-162.55
-139.4
-77.62
-75.11
Operating Margin (%)
- -
- -
- -
- -
- -
- -
- -
3
4
5
5
25
47
46
43
5
Depreciation Expense
-2
-4
-3
-4
-6
-7
-9
-17
-21
-21
-24
-50
-59
-59
-42
-44
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
-8,014.58
- -
- -
- -
- -
- -
-16,911.96
-3,440.2
-2,654.89
-4,680.81
-28,633.33
-417.01
-159.45
-137.78
-73.91
-73.77
Profit Margin (%)
1
1
4
5
18
51
32
17
29
5
40
22
70
54
54
52
Working Capital
1
1
1
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
LT Debt
1
5
10
16
36
73
63
47
55
80
56
217
223
164
121
109
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'24
Dec'24
Mar'25
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
230
230
230
Market Capitalization
119
90
130

Working Capital

FRC

•

in mil. unless spec.
Sep'24
Dec'24
Mar'25
Total Current Assets
66
67
66
Cash, Cash Equivalents & STI
45
48
46
Accounts Receivable, Net
10
10
10
Inventories
7
6
6
Total Current Liabilities
13
13
14
Payables & Accruals
- -
- -
- -
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
33.51%
41.29%
-25.94%
Free Cash Flow
- -
-12.07%
-80.03%
Net Income, GAAP
26.2%
22.8%
-28.41%
Sales/Revenue/Turnover
- -
2,871.61%
33.45%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
11
12
11
10
43
2024
13
15
14
15
57
2025
15
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
-0.06
-0.07
-0.06
-0.07
-0.26
2024
-0.05
-0.06
-0.04
-0.04
- -
2025
-0.05
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
Similar Companies
Agilent Technologies, Inc. (A)
Waters Corporation (WAT)
Amoy Diagnostics Co., Ltd. (300685.SZ)
Danaher Corporation (DHR)
IDEXX Laboratories, Inc. (IDXX)
Thyrocare Technologies Limited (THYROCARE.BO)
Business
IDL Diagnostics AB, formerly AroCell AB (publ), specializes in in vitro diagnostics, developing and marketing tests for cancer and bacterial diseases. The company offers the AroCell TK 210 ELISA, an immunoassay kit for measuring Thymidine Kinase 1 protein levels in blood, providing crucial insights for the prognosis and monitoring of various solid tumors like breast and prostate cancers. Additionally, its portfolio includes UBC® Rapid, a point-of-care test for bladder cancer, and TUBEX® TF, a swift diagnostic test for acute typhoid fever. Established in 2000 and headquartered in Uppsala, Sweden, the company has expanded its product offerings following the acquisition of IDL Biotech AB, with the proposed name change reflecting this broader diagnostic focus. This strategic move aims to leverage the established IDL brand and enhance its presence in global healthcare markets.